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Abstract
Background: Artesunate-amodiaquine (AS+AQ) and artemether-lumefantrine (AM-L) are efficacious artemisinin combination
therapy (ACT) regimens that have been widely adopted in sub-Saharan Africa. However, there is little information on the efficacy
of these regimens on subsequent episodes beyond 28 days, or on the safety of repeated treatments.
Methods: Children aged six months to 14 years with uncomplicated malaria were randomly assigned to treatment with AS+AQ
(n = 116), or AM-L (n = 111). Recruited subjects were followed-up, initially for 28 days, and then monthly for up to one year.
All subsequent attacks of uncomplicated malaria after 28 days were treated with the same regimen as at randomization.
Investigations aimed at determining efficacy and side effects were conducted.
Results: Adequate clinical and parasitological response in subjects with evaluable end-points were, 97.1% (100/103) and 98.2%
(107/109) on day 14, and 94.2% (97/103) and 95.3% (102/107) on day 28 in the AM-L and AS+AQ groups, respectively. Similar
results were obtained after PCR correction. The incidence of malaria attacks in the year following recruitment was similar
between the two treatment groups (p = 0.93). There was a high incidence of potentially AQ-resistant parasites in the study area.
The incidence of adverse events, such as pruritus, fatigue and neutropaenia were similar in the two treatment groups. No patient
showed signs of hearing impairment, and no abnormal neurological signs were observed during one year of follow-up. Other
adverse events were mild in intensity and overlapped with known malaria symptomatology. No adverse event exacerbation was
observed in any of the subjects who received multiple treatment courses with these ACT regimens during one year follow-up.
Conclusion: AS+AQ and AM-L were efficacious for treatment of children with uncomplicated malaria in Ghana and drug-
related adverse events were rare in treated subjects during one year of follow-up. The high prevalence of potentially AQ
resistant parasites raises questions about the utility of AQ as a partner drug for ACT in Ghana. The efficacy of AS+AQ in Ghana
requires, therefore, continuous monitoring and evaluation.
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Background
Artemisinin-based combination therapy (ACT) may slow
the development of resistance and reduce malaria trans-
mission [1]. Artesunate-amodiaquine (AS+AQ) and arte-
mether-lumefantrine (AM-L) are two ACT regimens that
have been widely adopted for the treatment of uncompli-
cated malaria across sub-Saharan Africa. The efficacies of
these two regimens are well established in trials of 14 or
28-day duration [2-4].
The efficacy of an ACT may depend on the level of pre-
existing resistance to the non-artemisinin component [5],
and it has been shown that, addition of an artemisinin
derivative to a failing antimalarial drug leads to an ineffec-
tive combination [6]. AS+AQ, which is the ACT that has
been adopted for first-line treatment of uncomplicated
malaria in Ghana [7], is considered efficacious when the
level of pre-existing resistance to AQ does not exceed 20%
[8]. However, there is declining efficacy of AQ mono-
therapy in Ghana, with a recent in vivo efficacy study of
AQ monotherapy in Ghana showing a cure rate below
50% [9].
The molecular basis underlying the mechanism of AQ
resistance has not been fully elucidated, but in vitro and in
vivo evidence suggests that AQ resistance is linked to the
T76 single nucleotide polymorphism in the Plasmodium
falciparum  chloroquine resistance transporter (Pfcrt)
[10,11]. Recently, a high Pfcrt T76 prevalence has been
reported from Ghana [12], raising questions about the
suitability and regional life span of AQ as a component of
ACT in Ghana. There is however only one published
report on the efficacy of AS+AQ from Ghana to date [13].
In spite of accumulating clinical experience and increasing
use of ACT, aspects of the safety of these regimens remain
a concern. With respect to artemisinins, high dose
parenteral administration of the oil-soluble derivatives is
associated with dose-dependent toxicity to areas of the
brain stem involved in coordination and balance in ani-
mals [14,15]. No convincing evidence of artemisinin neu-
rotoxicity has been demonstrated during routine clinical
use in humans. However, reports of abnormal neurologi-
cal signs in individual cases – each of which had underly-
ing pre-morbidity, or received concomitant therapy, have
been ascribed to artemisinin-based treatment in adults
[16-19]. There is lack of longitudinally collected data on
neurological findings in artemisinin-treated subjects,
especially in children, the sub-group of malaria-treated
patients that could be more susceptible to potential neu-
rotoxic injury [20].
With respect to AQ, prophylactic use of this drug has been
associated with fatal cases of agranulocytosis and hepati-
tis, mainly in non-immune adults [21,22]. Although it is
considered that agranulocytosis and hepatitis are unlikely
to occur when AQ is used for treatment [23], neutropae-
nia [24], as well as hepatitis [25], have been reported after
administration of treatment doses of AQ, alone or in com-
bination with AS. There is a lack of data on the natural his-
tory and clinical significance of reduced neutrophil counts
during AQ treatment, and there is no data on possible
cumulative neutrophil toxicity after repeated administra-
tion of treatment doses of AQ.
This study, conducted to generate efficacy and safety data
on AS+AQ and AM-L to support the new ACT policy in
Ghana, was a clinical trial with extended follow-up [26].
The design of the study allowed potential late-onset side
effects, as well as the effects of repeated treatments on
potential side effect occurrence to be evaluated. In addi-
tion, polymerase chain reaction (PCR) genotyping was
done to determine baseline haplotypic frequencies of Pfcrt
alleles in the study population.
Methods
Study site
The study was conducted in two primary health facilities,
Korle Bu Polyclinic (KBP) and Mamprobi Polyclinic
(MP). KBP is attached to a tertiary referral hospital, Korle
Bu Teaching Hospital (KBTH). The two facilities are situ-
ated in Ablekuma sub-district in Accra, Ghana. Both facil-
ities serve a mixed, predominantly low socio-economic
urban population. The study was conducted between
October 2004 and December 2006.
Study population
Children presenting with a history of fever to the facilities
were referred to the study team. A project physician exam-
ined the child to exclude concomitant illnesses. Subjects
were recruited if a blood film was positive for Plasmodium
falciparum, and if the study criteria were fulfilled.
Criteria
Inclusion criteria for the study were, age six months to 14
years; signs and symptoms of acute uncomplicated
malaria, including axillary temperature ≥37.5°C; con-
firmed P. falciparum mono-infection with parasite density
between 2,000 – 200,000/μL; and willingness to comply
with the follow-up schedule. Exclusion criteria were,
symptoms or signs of severe malaria; obvious clinical evi-
dence of chronic malnutrition or other severe disease;
known intolerance or allergy to study medications; and
reported treatment with any of the drugs under study one
month preceding enrolment. Children aged five to 14
years were included to permit objective neurologic exam-
ination and audiologic assessment. Schoolchildren aged
five to 14 years from two local primary schools were
enrolled as controls for the audiometric study described
below. Written informed consent was obtained from par-Malaria Journal 2008, 7:127 http://www.malariajournal.com/content/7/1/127
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ents or guardians of all subjects. Ethical approval for the
study was granted by the Ethical and Protocol Review
Committee of the University of Ghana Medical School.
Randomisation and blinding
A computer-generated simple randomization scheme was
prepared in advance. Allocated treatments were kept in
sealed opaque envelopes. After completion of formal
enrolment procedures, allocated treatments were admin-
istered by project nurses. All study personnel (except
project nurses), were unaware of the assigned treatments.
Treatment allocation
AQ (Camoquine®, Pfizer, Dakar, Senegal), 10 mg/kg body
weight, single daily dose for three days, was administered
with AS (Plasmotrim®, Mepha Ltd, Aesch-Basel, Switzer-
land), 4 mg/kg body weight, single daily dose, for three
days. AM-L (Coartem®, Novartis Pharma AG, Basel, Swit-
zerland; 20 mg artemether and 120 mg lumefantrine) was
administered at 0 and 8 hours on the first day, and then
twice daily for two subsequent days according to body
weight: 5–14 kg, one tablet/dose; 15–24 kg, two tablets/
dose; 25–34 kg, three tablets/dose; 35 kg and over, four
tablets/dose.
Project nurses administered all treatments (except the
evening dose of Coartem) in the clinic. Parents adminis-
tered the evening dose of Coartem® at home [27,28]. Chil-
dren were observed for 30 minutes after each drug
administration. Treatments were re-administered if the
child vomited. Children who vomited the re-ad minis-
tered dose were withdrawn. An extra Coartem® dose was
given to parents to re-administer at home if the child
should vomit.
Follow-up
Subjects were followed-up on days 1, 2, 3, 7, 14 and 28 for
clinical and laboratory assessments described below.
Children who missed their day 14 or day 28 follow-up
appointments were seen on days 15 or 29. After 28 days,
children were visited at home every month for up to one
year. During the monthly follow-up visits, parents or car-
egivers were asked about the child's well-being, behav-
ioural and developmental concerns, as well as open
questions about possible side event occurrence since the
last visit. A study physician examined children during the
follow-up visits. Follow-up was terminated if parents relo-
cated. Each time a subject presented with an acute febrile
illness during follow-up, thick films for malaria parasitae-
mia and a thorough examination was done, before and
after the episode. All episodes of uncomplicated malaria
diagnosed more than 28 days after treatment were treated
with the same pre-assigned regimen as at randomization.
Investigations
Neurological examination
Neurological examinations were done before treatment,
and then on days 1, 2, 3, 7, 14 and 28. The neurological
examination was focused on detecting abnormalities in
areas that have been implicated in artemisinin toxicity in
animals, i.e. on coordination and balance. In assessment
for nystagmus, the target was always kept within binocu-
lar vision; the direction of the fast phase of nystagmoid
eye movements was recorded; and it was noted if nystag-
mus was reduced by fixation or not. Any associated char-
acteristics, such as vertigo, nausea, vomiting, and tinnitus
were noted and recorded. Gait analysis, Romberg's test,
speech assessment and the finger-nose test were done to
evaluate cerebellar function. The finger-nose test was done
for children aged six years or older. The responses for the
finger-nose test were scored numerically for, 1) quality,
i.e. smoothness and signs of intention tremor during the
movement, and ii) adequacy, i.e. the successful imple-
mentation of the given task. The scores assigned for
smoothness were, 0 = no tremor; 1 = slight tremor towards
the end of the movement; and 2 = marked tremor increas-
ing towards the end of the movement. The scores ascribed
for adequacy were, 0 = the subject puts fingertip/pen top
correctly at tip of nose each time; 1 = subject misses the tip
of his/her nose/pen top once or twice; 2 = subject misses
the tip of his/her nose/pen top each time. A score of zero
for smoothness and adequacy was considered optimal for
children aged six years and above, and all tests were scored
with reference to the child's developmental age [29].
Audiometry
Pure tone, air conduction audiometry was done with a
portable screening audiometer (Kamplex KS8, P.C. Werth,
London, UK) for children aged five years and above who
could cooperate with the test, on days 0, 3, 7, and 28.
Hearing assessment was repeated after a follow-up period
ranging from nine months to one year. Hearing thresh-
olds were determined for each ear at the following fre-
quencies: 125 Hz, 250 Hz, 500 Hz, 750 Hz, 1000 Hz,
1500 Hz, 2 KHz, 3 KHz, 4 KHz, 6 KHz and 8 KHz.
Laboratory methods
Venous blood was collected into EDTA and heparinized
tubes on days 0, 3, 7, 14, 28 and on any day of recurrent
symptomatic parasitaemia. Parasite counts were deter-
mined in Giemsa-stained blood films relative to 200
white blood cells (WBC) and the measured WBC count.
Total WBC and differential counts were measured by
automated haematology analyzer (Cell Dyn, Abbott Lab-
oratories, USA). Serum aminotransferase and total
bilirubin were measured by a clinical chemistry analyzer
(EOS Bravo plus, Hospitex diagnostics, Italy).Malaria Journal 2008, 7:127 http://www.malariajournal.com/content/7/1/127
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Parasite genotyping
A nested PCR method was used to analyse polymor-
phisms in the merozoite surface protein (MSP) genes,
msp-1 and msp-2, to distinguish between recrudescent and
new infections, as described previously [30]. Nested PCR
with sequence specific oligonucleotide probe (SSOP)
ELISA was used to detect single nucleotide polymor-
phisms in the "C 72–76" position of the Pfcrt gene, as
described previously [31].
Efficacy outcome
The primary end-point was the unadjusted and PCR-
adjusted cure rates at days 14 and 28. Efficacy outcomes
were classified as, adequate clinical and parasitological
response (ACPR), early treatment failure (ETF), late clini-
cal failure (LCF) and late parasitological failure (LPF)
[32].
Secondary endpoints
Secondary endpoints were proportion of subjects with
fever and parasitaemia 24 and 48 hours after treatment,
the total number of subsequent malaria attacks in each
arm, and incidence of adverse events before and after 28
days.
All adverse events were graded by severity (mild, moder-
ate, severe, life-threatening), and relationship to study
medication (unrelated, unlikely, possible, probable, defi-
nitely related) [33].
Statistical analyses
The sample size was estimated on the assumption of a
negligible (3%) risk of treatment failure with AM-L
(because AM-L was new in the study area), and a 15% risk
of AS+AQ treatment failure (because of prior extensive use
of AQ monotherapy in the area). A sample size of 103
subjects was required to detect a 12% difference in cure
rates between AS+AQ and AM-L with 95% confidence and
80% power. Categorical variables were compared with the
chi square test with Yates correction or the Fisher's exact
test. Continuous variables were compared with the stu-
dent's t test or one-way analysis of variance. A logistic
modelling (GENMOD™) procedure was used to compare
the total number of treatments in the two arms for the
year of follow-up. Risk differences and 95% confidence
intervals were calculated with CIA™. Other analyses were
done with Sigma stat (version 3.1; Systat software Inc.,
Richmond, California, USA) and SAS (SAS Institute, Cary
NC, USA).
The primary efficacy outcome was analysed by a per-pro-
tocol (PP), and an intention-to-treat (ITT) method. In the
ITT analysis, subjects lost to follow-up were included;
these, as well as those withdrawn because of non-toler-
ance of oral medication, were considered treatment fail-
ures. In the PP analysis, only subjects with an assigned
outcome were included. The follow-up time of subjects
who did not complete one year of follow-up were cen-
sored at their last follow-up date. P values < 0.05 were
considered significant.
Results
Base line characteristics
A total of 227 subjects were randomized out of 846 sub-
jects screened. Sixteen subjects who were correctly rand-
omized did not complete 28 days follow-up. The reasons
for non-completion of follow-up in the AM-L arm were,
withdrawal due to persistent vomiting necessitating
parenteral treatment (n = 2); culture positive co-infection
with Salmonella typhi resulting in worsening clinical con-
dition after parasite clearance (n = 1); and loss to follow-
up (n = 5). The reasons for non-completion of follow-up
in the AS+AQ arm were, withdrawals due to persistent
vomiting (n = 2); withdrawal due to worsening clinical
condition despite rapid parasite clearance in an infant
who was subsequently admitted and managed clinically
for suspected septicaemia (n = 1); and loss to follow-up (n
= 6). The flow of subjects through the study (up to day 28)
is outlined (Figure 1). There were no differences in demo-
graphic and clinical parameters between the two groups
(Table 1). The proportion of subjects between the ages of
Table 1: Baseline characteristics of recruited subjects
Characteristic AM-L n = 111 AS+AQ n = 116 p
Male (n) 59 60
Female (n) 52 56
Age* (years) 5.2 (3–9) 6 (3.5–9.1) 0.72
Weight# (Kg) 19 (14–27.75) 18 (15–26) 0.66
Temperature# (°C) 38.6 (37.92–39) 38.7 (37.80–39.55) 0.19
Haemoglobin* (g/dL) 11.38 (2.21) 11.18 (1.96) 0.51
Parasitaemia# (/μL) 51408 (14377–115979) 60648 (20704–116496) 0.73
Total WBC count # (/μL) 8.9 (6.3–11.85) 9.1 (6.5–12.4) 0.95
Absolute neutrophil count# (/μL) 5411 (3541–7810) 5809 (4012–8236) 0.59
* Standard deviation, # rangeMalaria Journal 2008, 7:127 http://www.malariajournal.com/content/7/1/127
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five and 14 years was 50.4% (56/111) in the AM-L arm
and 55.2% (64/116) in the AS+AQ arm (p = 0.56).
Treatment outcomes
Day 14 and 28 cure rates
The proportion of subjects (PP analysis) with ACPR were,
97.1% (100/103) and 98.2% (107/109) on day 14 (p =
0.67); and 94.2% (97/103) and 95.3% (102/107) on day
28 (p = 0.94) in the AM-L and AS+AQ groups, respectively
(Table 2). The corresponding ACPR rates after PCR correc-
tion (PP analysis) on day 28 were, 96.1% (99/103) and
98.1% (105/107) (p = 0.43), respectively. The PCR-cor-
rected cure rates by ITT analysis on day 28 were, 90.1%
(100/111) and 91.3% (106/116) in the AM-L and AS+AQ
groups (0.91), respectively. There were no differences in
cure rates between younger children and children older
than five years.
Parasite clearance
Parasite clearance on days 1 and 2 (Figure 2) were similar
in the two groups.
Fever clearance
The proportion of subjects with fever was lower (though
not significantly) in the AS+AQ group after 24 hours
(5.3%) than in the AM-L (14.6%) group (p = 0.06). The
trend had disappeared after 48 hours (p = 0.32).
Symptomatic infections after day 28
After one year of follow-up, there were 34 further episodes
of symptomatic uncomplicated malaria in 93 subjects
(incidence rate, 0.37 per year) in the AS+AQ group, and
Trial profile Figure 1
Trial profile. AM-L = artemether-lumefantrine, AS+AQ = artesunate+amodiaquine.
846 children assessed for eligibility
227 children randomized
111 received AM-L
2 withdrawn; persistent vomiting
2 lost to follow up day 1
1 lost to follow up day 3
1 salmonella sepsis day 5
2 lost to follow up day 7
103 evaluable day 14
103 evaluable day 28
116 received AS+AQ
2 withdrawn; persistent vomiting
1 lost to follow up day 1
1 probable sepsis day 3
3 lost to follow up day 7
109 evaluable day 14
2 lost to follow up day 28
107 evaluable day 28
Table 2: Efficacy outcomes (per protocol analysis) on days 14 and 
28
Day 14 AM-L AS+AQ
ACPR 100 107
ETF 0 0
LCF 1 0
LPF 2 2
Day 28
ACPR 97 102
ETF 0 0
LCF 3 1
LPF 3 4
AM-L = artemether-lumefantrine, AS+AQ = artesunate+amodiaquine
Day 28 cure rates are cumulative figures from day 14. ACPR = 
adequate clinical and parasitological response, ETF = early treatment 
failure, LCF = late clinical failure, LPF = late parasitological failureMalaria Journal 2008, 7:127 http://www.malariajournal.com/content/7/1/127
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28 episodes in 82 subjects (incidence rate, 0.34 per year)
in the AM-L group (incidence ratio, 0.93). Similar results
were obtained, when logistic modelling (p = 0.94), or sur-
vival analysis (p = 0.76) was used to compare incidence in
the two arms. All subjects who received repeat treatment
courses responded appropriately to treatment. The time to
a repeat treatment episode (median; interquartile range)
was longer in the AS+AQ (91 days; 53–193 days) arm
than the AM-L (64 days; 33–88 days) arm. There were
three sibling pairs among those who were treated for
repeat infections. These siblings (each randomized to
receive a different ACT) reported simultaneously with a
repeat attack of uncomplicated malaria.
Pfcrt haplotypes
The "CVIET" (mutant) haplotype was present in 72.1%
(75/104) of pre-treatment samples in subjects treated
with AS+AQ. The effect of the "CVIET" haplotype preva-
lence on treatment outcome could not be evaluated
because of the low number of subjects with treatment fail-
ure.
Safety assessment
Audiometry
Audiometry could be done in 72 subjects (AS+AQ, n = 37;
AM-L, n = 35). Hearing thresholds were significantly ele-
vated in treated subjects than in age- and sex-matched
control children on days 0, 3, 7, and 28, but there were no
differences between hearing thresholds of subjects and
controls after nine to 12 months. The full details of the
audiometric study will be presented in another report.
Neurological examination
Neurological examination could be done for 168 children
(AS+AQ, 92; AM-L, 76). Nystagmus was observed in two
subjects (AM-L, n = 1, AS+AQ, n = 1) between days one
and seven. A detailed history indicated that one of these
two subjects (7-year-old male; AS+AQ treated) was admit-
ted as a neonate into neonatal intensive care (NICU)
because of probable birth asphyxia. This subject was still
attendant at pre-school at seven years of age (which is
unusual in Ghana), and demonstrated excessive emo-
tional lability. An electroencephalography (EEG) done for
this subject because of a history suggesting the possibility
of a seizure disorder, reported the presence of "epilepti-
form loci and generalized cerebral dysfunction". The
Parasite clearance in the two groups Figure 2
Parasite clearance in the two groups. AS+AQ = amodiaquine+artesunate, AM-L = artemether lumefantrine.Malaria Journal 2008, 7:127 http://www.malariajournal.com/content/7/1/127
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other subject with nystagmus (9-year-old male, AM-L
treated), also had a history of NICU admission for macro-
somia (birth weight 4.5 kg) and possible neonatal
hypoglycaemia. This subject had poor academic perform-
ance (had repeated first and second grades in school) and
possible cognitive impairment. A routine EEG done for
this subject was normal. A positive Romberg's test (which
may suggest sensory ataxia) was noticed on day 3 in an 11-
year old female (AM-L). This child was not attending
school (despite her age) and had a history suggestive of
possible cognitive impairment. No other abnormal neu-
rological findings were observed in the remaining chil-
dren during the 28-days follow-up, monthly follow-up
visits, or for subjects who received multiple treatments.
Neutrophil counts
There were no differences in the mean total WBC or abso-
lute neutrophil counts between the two groups on days 0,
3, 7, 14 or 28 (Figure 3). Neutrophil counts on follow-up
days 3, 7, 14 and 28 were significantly lower (p < 0.01)
compared with day 0 counts in both treatment arms. Pre-
treatment neutropaenia was observed in three subjects
(AM-L, n = 2; AS+AQ, n = 1) on admission. Between days
3 and 28, neutropaenia was observed in 13 (11.7%) and
14 (12.6%) subjects in the AS+AQ and AM-L groups,
respectively (p = 0.90). The median pre-treatment neu-
trophil count of subjects who developed neutropaenia
was lower than subjects who did not develop neutropae-
nia, but the mean age was similar. Neutropaenia was
severe (<500/μL) in three subjects (AM-L, n = 2; AS+AQ, n
= 1) between days 3 and 28. Neutrophil counts did not
show any pattern of difference between the initial and
subsequent episodes of uncomplicated malaria in subjects
who were treated more than once (data not shown). In
two subjects, each of which was treated for five episodes
of uncomplicated malaria (with AS+AQ) during the one-
year follow-up, no clinical signs suggestive of neutropae-
nia was noticed, and all neutrophil count measurements
were higher than 1,000/μL in these two subjects. The neu-
trophil count profile of one of these individuals is shown
(Figure 4).
Clinical chemistry
Serum alanine aminotransferase, aspartate aminotrans-
ferase and total bilirubin were initially (day 0) elevated,
but there were no differences between the two treatment
groups. The liver enzymes did not increase in response to
treatment, but showed a trend towards normalization
(reduction) as clinical symptoms improved (data not
shown).
Neutrophil count profiles in the two groups Figure 3
Neutrophil count profiles in the two groups. AS+AQ = amodiaquine+artesunate, AM-L = artemether-lumefantrine. Ver-
tical error bars represent 95% confidence intervals.Malaria Journal 2008, 7:127 http://www.malariajournal.com/content/7/1/127
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Other adverse events
Within the first three days of treatment, complaints of diz-
ziness were reported by 14 (12%) and eight (7.2%) sub-
jects in the AS+AQ and AM-L groups, respectively (p =
0.31). Complaints of fatigue and excessive sleepiness were
reported by five (4.3%) and four (3.6%) subjects in the
AS+AQ and AM-L groups, respectively (p = 1.0). Pruritus
was reported by three (AS+AQ, n = 2; AM-L, n = 1) sub-
jects. A history of vomiting and nausea was part of the pre-
senting complaint by 44.8% (52/116) and 40.5% (45/
111) subjects respectively in the AS+AQ and AM-L groups
on admission (p = 0.74). Between the first three days of
treatment, 27.5% (32/116) and 12.6% (14/111) subjects
respectively complained of vomiting and or nausea in the
AS+AQ and AM-L groups (p = 0.01). Severe anaemia (hae-
moglobin 4.8 g/dl) occurred on day 14 in a 1.5 year old
subject (AS+AQ). Severe anaemia and dizziness were con-
sidered unlikely to be drug related, but pruritus and exces-
sive sleepiness were considered possibly drug-related.
Other reported adverse events were mild in intensity, and
overlapped with known malarial symptomatology. These
were mostly classified as unrelated to study medications.
Discussion
This study provides efficacy data on AS+AQ and AM-L, the
two most widely adopted ACT regimens in sub-Saharan
Africa, for Ghanaian children. The study also provides
longitudinally collected safety data on neutrophil counts
and neurological findings for Ghanaian children with
uncomplicated malaria treated with repeated courses of
these two ACT regimens.
The results showed a high cure rate for both regimens after
a standard 14- or 28-day follow-up. These results are con-
sistent with efficacy results reported from several sub-
Saharan African countries [2-4,34], indicating a high over-
all cure rate with these regimens in the short (28-day)
term. Because efficacy estimates could vary depending on
the statistical analyses used to assess treatment outcome
[35], and because recent guidelines recommend a change
in treatment policy when failure rates exceed 10% [8], the
use of the PP as well as an ITT analysis provided efficacy
estimates that could be considered robust and operation-
ally useful.
Neutrophil count profile in a subject who was treated for five episodes of uncomplicated malaria with AS+AQ Figure 4
Neutrophil count profile in a subject who was treated for five episodes of uncomplicated malaria with AS+AQ. 
arrows point to the dates the subject presented with episodes.Malaria Journal 2008, 7:127 http://www.malariajournal.com/content/7/1/127
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The finding of a high prevalence of potentially AQ-resist-
ant parasites in this southern Ghanaian population raises
questions about the long-term utility of AQ as a partner
drug for ACT in Ghana, a question that has also been
raised by other investigators from northern Ghana [9],
where a similarly high Pfcrt mutant allele prevalence has
been detected [12]. Although the impact of mutant Pfcrt
allele prevalence on treatment outcome in the group
treated with AS+AQ could not be assessed because of the
low incidence of treatment failures in this group, AS+AQ
has been associated with a high cure rate in an area of even
higher (90%) Pfcrt K76T mutant prevalence [36]. This sug-
gests that the high cure rate of the AS+AQ combination is
due mainly to the effect of the artemisinin component.
Recent evidence also suggests a differential selective pat-
tern of parasite sensitivity for different ACT regimens [37].
Thus, it may be difficult to predict, or extrapolate in vivo
efficacy of AS+AQ from one area to another, highlighting
the need to generate local efficacy data for these newly
introduced treatment regimens in Ghana. Furthermore,
the high mutant Pfcrt allele prevalence also provides addi-
tional evidence justifying the treatment policy change in
Ghana to ACT.
Previous studies that have compared AS+AQ with AM-L
over a follow-up duration of 28-days or longer have dem-
onstrated a lower re-infection rate for AM-L [2,4]. Other
studies that have compared AM-L with ACT regimens con-
sisting of longer-acting partner drugs have demonstrated a
shorter time to re-infection for AM-L [38-40]. The longer
time to a repeat clinical episode in the AS+AQ arm in this
study could reflect the differences in chemoprophylaxis
afforded by AQ, which has a relatively longer half-life. The
possible implication of this finding is that, follow-up
times required to detect subtle differences in efficacy
between different ACT regimens, may need to be length-
ened.
There was a drop in neutrophil counts in both arms after
treatment. This pattern of neutrophil count reduction, as
well as the absence of differences in neutrophil count pro-
files between children who received single course and
those who received multiple courses, suggests the possi-
bility of a disease-rather than drug-related effect.
Malaria-associated neutropaenia has been reported for
subjects treated with AQ, either as monotherapy, or in
combination with AS [24], as well as for subjects treated
with AM-L [41] or with other antimalarials [42]. Neu-
trophil count reduction during acute malaria may be due
to altered intravascular granulocyte distribution [43], or
to enhanced phagocytosis [44]. AQ-associated agranulo-
cytosis on the other hand, may be due to inhibition of
bone marrow precursor cells [45,46], or to immune-medi-
ated hypersensitivity [47,48]. The finding that neutrophil
counts were not increasingly reduced in subjects who
received more than one treatment course in this study
lends support to the conclusion that, brief three-day
administration of AQ, as used for treatment, is unlikely to
be associated with the described side effects observed dur-
ing prophylaxis [23]. However, there was a large random
variability around the confidence interval of the difference
in neutropaenia incidence between the groups, and the
sample size of the study was not sufficient to detect rare
events; therefore, this potential side effect should be con-
tinuously monitored.
This is one of the few studies to conduct systematic longi-
tudinal neurological examinations for children treated
with artemisinin-based regimens. A total follow-up last-
ing 12 months did not reveal abnormal neurological signs
that could be ascribed to artemisinin-based treatment in
this study. The two subjects with observed nystagmus had
underlying conditions that could easily explain the noted
abnormalities. Furthermore, the observed nystagmus was
not associated with other cerebellar signs, suggesting these
were unlikely to be of clinical significance, or could be
false positive due, for instance, to excessive lateral eye
abduction. However, nystagmus has been reported in
artemisinin-treated subjects without reported underlying
neurological abnormality [49], as well as in an experimen-
tal study of artemisinin-treated rhesus monkeys [50].
Because available data from animal studies do not pro-
vide much insight into the early signs of possible artemisi-
nin-related neurotoxicity, and because of the lack of a
well-defined neurological syndrome to characterize
potential late artemisinin toxicity during clinical use,
detailed focused studies on this subject are still required.
The incidence of gastrointestinal adverse events was
higher in the AS+AQ group compared to the AM-L group,
similar to a recent report comparing AS+AQ with dihy-
droartemisinin-piperaquine [51]. This may suggest a
lower intrinsic tolerance of AS+AQ, or could be due to the
differences in drug formulation, as AS+AQ was a co-
administered regimen, whilst the AM-L was co-formu-
lated.
The limitations of this study include its limited statistical
power to detect rare side effects, as well as the difficulties
associated with evaluating neurological function in the
younger children below five years of age. Further studies
of the nystagmoid eye movements, apart from the clinical
observations done, would also be useful.
Conclusion
AS+AQ and AM-L were efficacious for the treatment of
Ghanaian children with uncomplicated malaria. After 12
months of detailed systematic follow-up, no overt clinical
evidence of neurotoxicity or neutropaenia was observed.Malaria Journal 2008, 7:127 http://www.malariajournal.com/content/7/1/127
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However, the sample size was limited for conclusive evi-
dence on safety; therefore, post-marketing surveillance,
with particular emphasis on neurological and haemato-
logical changes, is still indicated. In view of the high prev-
alence of potentially AQ-resistant mutant parasites in the
study area, the efficacy of the AS+AQ combination, the
first-line treatment for uncomplicated malaria in Ghana,
requires continuous monitoring and evaluation.
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